drugset / Trial / NCT00279825

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

NCT00279825

Phase 2 Completed 16 enrolled Impax Laboratories, LLC
RandomizedCrossoverTriple-blindTreatment

Summary

The objective of this study is to compare the pharmacokinetics and pharmacodynamics of IPX054, carbidopa-levodopa immediate-release tablets, and carbidopa-levodopa controlled-release tablets in subjects with idiopathic Parkinson's disease.

Timeline

Start
2006-01
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CD-LD CR Unknown 50 mg
Subject CD-LD CR Unknown 200 mg
Subject IPX054 Unknown 200 mg
Subject IPX054 Unknown 250 mg
Subject Levodopa Small molecule 25 mg
Subject Levodopa Small molecule 100 mg

Indications